nach oben

Erschienen in:

01.12.2014 | main topic

Renal denervation in the treatment of resistant arterial hypertension

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 23-24/2014

Einloggen, um Zugang zu erhalten

Summary

Patients with resistant arterial hypertension have an increased risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. In many cases, limitations of pharmacological treatment like intolerance and adherence to the antihypertensive medications are present in the clinical setting. In this context, new treatment options like trans-femoral sympathetic renal nerve denervation is, even after publication of the Symplicity HTN-3 trial, a promising new treatment option.

Vorheriger Artikel Electrical carotid baroreceptor stimulation

Nächster Artikel Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review

Rodgers A, Ezzati M, Vander Hoorn S, et al.: Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med. 2004 Oct;1(1):e27. Epub 2004 Oct 19.

The Task Force for the Management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.CrossRef

Kintscher U. The burden of hypertension. Eurointervention. 2013;9:R12–5.PubMedCrossRef

Chobanian AV, Bakris GL, Black HR, et al. Seventh report of Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef

Persell SD. Prevalence of resistant hypertension in the United States 2003–2008. Hypertension. 2011;57:1076–80.PubMedCrossRef

Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42.PubMedCentralPubMedCrossRef

Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60(1):34–41.PubMedCentralPubMedCrossRef

Mazzaglia G, Ambrosioni E, Alaqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.PubMedCrossRef

De Geest S, Ruppar T, Berben L, et al. Medication non-adherence as a critical factor in the management of presumed resistant hypertension: a narrative review. Eurointervention. 2014;9:1102–9.PubMed

10.

Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217–22.PubMedCrossRef

11.

Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–66.PubMedCrossRef

12.

Schlaich M, Sobotka P, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.PubMedCrossRef

13.

DiBona GF, Esler M. Translational medicine. The antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–53.PubMedCrossRef

14.

Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846–51.PubMedCrossRef

15.

Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999–2005.PubMedCentralPubMedCrossRef

16.

Schlaich M, Sobotka P, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.PubMedCrossRef

17.

Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef

18.

Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1:403–8.PubMedCrossRef

19.

Krum H, Schlaich M, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):602–9.CrossRef

20.

Esler M, Krum H, Sobotka P, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903–1909.PubMedCrossRef

21.

Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–1946.

22.

Witkowski A, Prejbisz, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRef

23.

Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Col Cardiol. 2012;59:901–9.CrossRef

24.

Mahfoud F, Vonend O, Kintscher U, et al. Kriterien der Deutschen Gesellschaft für Kardiologie, Deutschen Hochdruckliga e.V. DHL/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologiezur Zertifizierung von „Renale Denervations-Zentren (RDZ)“. Der Kardiologe. 2013;7:429–34.CrossRef

25.

Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;307(15):1393–401.CrossRef

26.

Gulati V, White WB. Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens. 2013;7(6):484–93.PubMedCrossRef

27.

Eleid MF, Schwartz GL, Gulati R. Renal denervation for hypertension. Curr Probl Cardiol. 2014;39:35–51.PubMedCrossRef

28.

Bertrog SC, Sobotka PA, Sievert H. Renal denervation for hypertension. J Am Coll Cardiol Intv. 2012;5:249–58.CrossRef

29.

Worthley S. Safety and efficacy of a novel quadrapolar renal denervation catheter in patients with resistant hypertension: a first in man multicenter study. Abstract presented at the 2012 Annual Scientific Sessions of the European Association for Percutaneous Cardiovascular Interventions. Pairs, France; May 16, 2012.

30.

Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150–6.PubMedCentralPubMedCrossRef

31.

Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.PubMedCrossRef

32.

Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250–7.PubMedCentralPubMedCrossRef

33.

Bhamra-Arizy P, Rao S, Muller DW. Renal artery stenosis following renal percutaneous denervation. Catheter Cardiovasc Interv. 2014; May 14. doi:10.1002/ccd.25546 (Epub ahead of print).

34.

Lambert T, Blessberger H, Grund M, et al. Late renal artery stenosis after percutaneous renal denervation. J Cardiovasc Med; 2014 (Epub ahead of print).

35.

Ukena C, Cremers B, Ewen S, et al. Response and non-response to renal denervation: who is the ideal candidate? Eurointervention. 2013;9:R54–7.PubMedCrossRef

36.

Lambert T, Blessberger H, Gammer V, et al. Effects of renal denervation on ambulatory blood pressure measurements in patients with resistant hypertension. Clin Cardiol. 2014;37(5):307–11.PubMedCrossRef

37.

Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–40.PubMedCrossRef

38.

39.

Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.PubMedCrossRef

40.

Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712–8.PubMedCrossRef

41.

Kario K, Lowy A, Munk VC, et al. 24-hour blood pressure control—a predictor for clinical outcomes. Curr Hypertens Rev. 2009;5:102–22.CrossRef

42.

Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension. 2006;47:846–53.PubMedCrossRef

43.

Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension. 2000;36:894–900.PubMedCrossRef

44.

Ohkubo T, Hozawa A, Nagai K, et al. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens. 2000;18:847–54.PubMedCrossRef

45.

Weber T, Zweiker R, Koppelstätter C, et al. Renale Sympathikusdenervierung 2014 in Österreich: Update der Empfehlungen der Österreichischen Gesellschaft für Hypertensiologie. Austrian J Hypertens. 2014;18(2):54–60.

Titel: Renal denervation in the treatment of resistant arterial hypertension
Publikationsdatum: 01.12.2014
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 23-24/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-014-0330-9

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23-24/2014

Carotid interventions and blood pressure

Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review

Professor Gerhart Hitzenberger zum 85. Geburtstag

Relapsing advanced metatypical basal cell carcinomas (MTBCC) of the face: Surgical modalities

Stellungnahme zu Schwarz E., Maier M. – Publication output in the field of Public Health and its appreciation at political level in Austria, Wien Med Wochenschr (2014) 164:123–130

Stellungnahme zu Schwarz E., Maier M. – Publication output in the field of Public Health and its appreciation at political level in Austria, Wien Med Wochenschr (2014) 164:123–130